Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction

Type 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwalla, Anjali, Gruen, Jadry, Peters, Carli, Sinnenberg, Lauren, Owens, Anjali T, Reza, Nosheen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2022
Materias:
Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006126/
https://www.ncbi.nlm.nih.gov/pubmed/35433030
http://dx.doi.org/10.15420/cfr.2021.31
_version_ 1784686603243880448
author Agarwalla, Anjali
Gruen, Jadry
Peters, Carli
Sinnenberg, Lauren
Owens, Anjali T
Reza, Nosheen
author_facet Agarwalla, Anjali
Gruen, Jadry
Peters, Carli
Sinnenberg, Lauren
Owens, Anjali T
Reza, Nosheen
author_sort Agarwalla, Anjali
collection PubMed
description Type 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic agents has led to an emergence of novel therapies with robust benefits in heart failure, and clinicians must now ensure they are familiar with the management of patients with concurrent diabetes and stage C HFrEF. This review summarises the current evidence for the management of type 2 diabetes in stage C HFrEF, recapitulating data from landmark heart failure trials regarding the use of guideline-directed medical therapy for heart failure in patients with diabetes. It also provides a preview of upcoming clinical trials in these populations.
format Online
Article
Text
id pubmed-9006126
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-90061262022-04-15 Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction Agarwalla, Anjali Gruen, Jadry Peters, Carli Sinnenberg, Lauren Owens, Anjali T Reza, Nosheen Card Fail Rev Therapy Type 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic agents has led to an emergence of novel therapies with robust benefits in heart failure, and clinicians must now ensure they are familiar with the management of patients with concurrent diabetes and stage C HFrEF. This review summarises the current evidence for the management of type 2 diabetes in stage C HFrEF, recapitulating data from landmark heart failure trials regarding the use of guideline-directed medical therapy for heart failure in patients with diabetes. It also provides a preview of upcoming clinical trials in these populations. Radcliffe Cardiology 2022-03-28 /pmc/articles/PMC9006126/ /pubmed/35433030 http://dx.doi.org/10.15420/cfr.2021.31 Text en Copyright © 2022, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Therapy
Agarwalla, Anjali
Gruen, Jadry
Peters, Carli
Sinnenberg, Lauren
Owens, Anjali T
Reza, Nosheen
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
title Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
title_full Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
title_fullStr Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
title_full_unstemmed Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
title_short Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
title_sort management of type 2 diabetes in stage c heart failure with reduced ejection fraction
topic Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006126/
https://www.ncbi.nlm.nih.gov/pubmed/35433030
http://dx.doi.org/10.15420/cfr.2021.31
work_keys_str_mv AT agarwallaanjali managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction
AT gruenjadry managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction
AT peterscarli managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction
AT sinnenberglauren managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction
AT owensanjalit managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction
AT rezanosheen managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction

Ejemplares similares